Found: 15
Select item for more details and to access through your institution.
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 1, doi. 10.1007/s00280-021-04375-2
- By:
- Publication type:
- Article
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 11, doi. 10.1007/s00280-021-04359-2
- By:
- Publication type:
- Article
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 21, doi. 10.1007/s00280-021-04362-7
- By:
- Publication type:
- Article
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 31, doi. 10.1007/s00280-021-04363-6
- By:
- Publication type:
- Article
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 41, doi. 10.1007/s00280-021-04361-8
- By:
- Publication type:
- Article
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 49, doi. 10.1007/s00280-021-04350-x
- By:
- Publication type:
- Article
4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 59, doi. 10.1007/s00280-021-04367-2
- By:
- Publication type:
- Article
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 71, doi. 10.1007/s00280-021-04368-1
- By:
- Publication type:
- Article
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 83, doi. 10.1007/s00280-021-04373-4
- By:
- Publication type:
- Article
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 93, doi. 10.1007/s00280-021-04358-3
- By:
- Publication type:
- Article
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 105, doi. 10.1007/s00280-021-04369-0
- By:
- Publication type:
- Article
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 117, doi. 10.1007/s00280-021-04370-7
- By:
- Publication type:
- Article
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 129, doi. 10.1007/s00280-021-04365-4
- By:
- Publication type:
- Article
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 1, p. 141, doi. 10.1007/s00280-021-04376-1
- By:
- Publication type:
- Article
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice